Thus, the differences in the responses to immune checkpoint inhibitors of Chinese patients with different cervical cancer subtypes could be caused by the variance in gene alterations, PD-L1 expression and TMB status across different subtypes. The gene discussed is CD274; the disease is cervical cancer.